Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Progress in the development of a cervical cancer vaccine

Authors Ursula Winters, Richard Roden, Henry Kitchener, Peter Stern

Published 15 September 2006 Volume 2006:2(3) Pages 259—269

Ursula Winters1, Richard Roden2, Henry Kitchener3, Peter Stern1

 

1CRUK Immunology Group, Paterson Institute for Cancer Research, Manchester, UK; 2Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, USA; 3Department of Gynaecological Oncology, University of Manchester, St Mary’s Hospital, Manchester, UK

 

Abstract: Persistent infection by ‘high risk’ genotypes of human papilloma virus (HPV) is necessary but not sufficient for the development of over 98% of cervical cancers. Thus the development of vaccines that prevent HPV transmission represent an important opportunity to prevent cervical cancer. There are several prophylactic HPV vaccine formulations based upon L1 virus-like particles (VLPs) currently in phase III trials and recently released data are extremely promising. However, many practical issues surrounding implementation of these vaccines need to be addressed including, who and when to vaccinate, duration of protection, and integration with current screening programs. The vaccines currently being evaluated target the two most prevalent high risk HPV types which are responsible for approximately 70% of cervical cancers. To increase the breadth of protection, it is likely that L1 VLPs of other viral subtypes must be included, although vaccines targeting the conserved regions of the L2 minor capsid protein warrant further exploration in this regard. In addition the vaccines nearing licensing will not combat established HPV-related disease and a therapeutic vaccine, of which there are several candidates in early stages of development, would be desirable. This review discusses the background to and progress in vaccine development and the issues surrounding the introduction of HPV vaccines.

 

Keywords: HPV, cervical cancer, vaccine

Download Article [PDF] 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

Hae-Hyuk Lee, Torsten Zuberbier, Margitta Worm

Therapeutics and Clinical Risk Management 2007, 3:1021-1026

Published Date: 15 January 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008

How should we measure medication adherence in clinical trials and practice?

Jeannie K Lee, Karen A Grace, Terri G Foster, Monica J Crawley, Goldina I Erowele, et al

Therapeutics and Clinical Risk Management 2007, 3:685-690

Published Date: 15 September 2007

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:335-336

Published Date: 15 December 2006

An assessment of the cost-utility of therapy for psoriasis

Stefan C Weiss, Wingfield Rehmus, Alexa B Kimball

Therapeutics and Clinical Risk Management 2006, 2:325-328

Published Date: 15 September 2006

Bortezomib (Velcade™) in the treatment of multiple myeloma

Antonia Field-Smith, Gareth J Morgan, Faith E Davies

Therapeutics and Clinical Risk Management 2006, 2:271-279

Published Date: 15 September 2006